Department of Pediatrics, Shanghai Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine.
Guru Gobind Singh Medical College, Punjab, India.
Acta Biomed. 2021 Sep 2;92(4):e2021271. doi: 10.23750/abm.v92i4.11787.
As the world continues to struggle with the pandemic of COVID-19 (coronavirus disease 2019), several cases of mucormycosis have been reported in these patients with a high mortality rate. We conducted a review of literature and found 19 articles with 20 patients who developed mucormycosis during their COVID-19 infection.14 (70%) were males, and 6(30%) were females. While their mean age was 52.2 ± 17.3, affected men were older than females. Ten (50%) patients also had diabetes. Common clinical findings included ophthalmologic complaints, fever, shortness of breath, and facial pain. Amphotericin B was the most common antifungal used and 40% of cases needed surgical management of the infection. Steroid use was reported in around 12 cases (60%). Unfortunately, the mortality rate was 65% in this group of patients. Several changes in care should be brought for a consistent prevention, early diagnosis, and strong management of mucormycosis in COVID-19 patients.
随着世界继续与 COVID-19（2019 年冠状病毒病）大流行作斗争，在这些具有高死亡率的患者中已经报告了几例毛霉菌病病例。我们对文献进行了回顾，发现有 19 篇文章和 20 例 COVID-19 感染期间发生毛霉菌病的患者。14 例（70%）为男性，6 例（30%）为女性。尽管他们的平均年龄为 52.2±17.3，但患病男性比女性年长。10 例（50%）患者还患有糖尿病。常见的临床发现包括眼科投诉、发热、呼吸急促和面部疼痛。两性霉素 B 是最常用的抗真菌药，40%的病例需要对感染进行手术治疗。约有 12 例（60%）报告使用了类固醇。不幸的是，该组患者的死亡率为 65%。在 COVID-19 患者中，应采取一些护理方面的改变，以进行一致的预防、早期诊断和加强毛霉菌病的管理。
